|
CA2406687A1
(en)
*
|
2001-11-09 |
2003-05-09 |
Transgene S.A. |
Chimeric promoters for controlling expression in muscle cells
|
|
US20080044393A1
(en)
*
|
2004-07-16 |
2008-02-21 |
White Robert L |
Retinal dystrophin transgene and methods of use thereof
|
|
US8557969B2
(en)
|
2004-12-01 |
2013-10-15 |
The Regents Of The University Of Michigan |
Compositions and methods for regulating cardiac performance
|
|
WO2008054713A2
(en)
*
|
2006-10-30 |
2008-05-08 |
Thomas Jefferson University |
Tissue specific gene therapy treatment
|
|
US20120322861A1
(en)
*
|
2007-02-23 |
2012-12-20 |
Barry John Byrne |
Compositions and Methods for Treating Diseases
|
|
WO2012136811A1
(en)
|
2011-04-06 |
2012-10-11 |
Universite Pierre Et Marie Curie (Paris 6) |
A skeletal muscle-specific enhancer
|
|
EP4124346A3
(en)
*
|
2012-06-19 |
2023-04-19 |
University of Florida Research Foundation, Inc. |
Compositions and methods for treating diseases
|
|
EP2885008B1
(en)
|
2012-08-15 |
2018-11-07 |
University Of Virginia Patent Foundation |
Compositions and methods for treating peripheral arterial disease
|
|
CN106414739A
(zh)
|
2012-12-20 |
2017-02-15 |
萨雷普塔医疗公司 |
用于治疗肌营养不良症的改良的外显子跳跃组合物
|
|
EP3760720A1
(en)
|
2013-03-14 |
2021-01-06 |
Sarepta Therapeutics, Inc. |
Exon skipping compositions for treating muscular dystrophy
|
|
US9217148B2
(en)
|
2013-03-14 |
2015-12-22 |
Sarepta Therapeutics, Inc. |
Exon skipping compositions for treating muscular dystrophy
|
|
WO2015035364A1
(en)
*
|
2013-09-09 |
2015-03-12 |
University Of Washington Through Its Center For Commercialization |
Proteins for targeting neuronal nitric oxide synthase to muscle sarcolemma and related methods of use
|
|
AU2015208247B2
(en)
|
2014-01-21 |
2021-05-27 |
Universiteit Gent |
Muscle-specific nucleic acid regulatory elements and methods and use thereof
|
|
US10472408B2
(en)
|
2015-03-05 |
2019-11-12 |
Peter Und Traudl Engelhorn-Stiftung Zur Förderung Der Lebenswissenschaften |
Fusion proteins comprising partial tetraspanin sequences and a system thereof for presenting peptides on the cell surface
|
|
GB201508025D0
(en)
|
2015-05-11 |
2015-06-24 |
Ucl Business Plc |
Fabry disease gene therapy
|
|
CN104894651B
(zh)
*
|
2015-06-29 |
2017-04-12 |
天津诺禾医学检验所有限公司 |
微量起始dna的高通量测序文库构建方法及其所构建的高通量测序文库
|
|
KR102799163B1
(ko)
*
|
2015-09-17 |
2025-04-21 |
더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 |
Galgt2 유전자 치료 방법 및 물질
|
|
AU2017250017B2
(en)
|
2016-04-14 |
2022-12-22 |
Benitec IP Holdings Inc. |
Reagents for treatment of oculopharyngeal muscular dystrophy (OPMD) and use thereof
|
|
WO2017223128A1
(en)
|
2016-06-21 |
2017-12-28 |
The Curators Of The University Of Missouri |
Modified dystrophin proteins
|
|
US11512327B2
(en)
|
2017-08-03 |
2022-11-29 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of AAV
|
|
WO2019079242A1
(en)
|
2017-10-16 |
2019-04-25 |
Voyager Therapeutics, Inc. |
TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
|
|
TW202413649A
(zh)
|
2017-10-16 |
2024-04-01 |
美商航海家醫療公司 |
肌萎縮性脊髓側索硬化症(als)之治療
|
|
CN111936621B
(zh)
|
2018-02-05 |
2025-05-13 |
奥登茨治疗公司 |
转录调控元件和它的用途
|
|
CA3086942A1
(en)
|
2018-02-07 |
2019-08-15 |
Genethon |
Hybrid regulatory elements
|
|
CA3097192A1
(en)
|
2018-04-27 |
2019-10-31 |
Voyager Therapeutics, Inc. |
Methods for measuring the potency of aadc viral vectors
|
|
WO2019222329A1
(en)
|
2018-05-15 |
2019-11-21 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
|
CN112424359A
(zh)
|
2018-05-15 |
2021-02-26 |
沃雅戈治疗公司 |
用于治疗帕金森氏病的组合物和方法
|
|
WO2019241486A1
(en)
|
2018-06-13 |
2019-12-19 |
Voyager Therapeutics, Inc. |
Engineered 5' untranslated regions (5' utr) for aav production
|
|
US20210254103A1
(en)
|
2018-07-02 |
2021-08-19 |
Voyager Therapeutics, Inc. |
Treatment of amyotrophic lateral sclerosis and disorders associated with the spinal cord
|
|
WO2020072849A1
(en)
|
2018-10-04 |
2020-04-09 |
Voyager Therapeutics, Inc. |
Methods for measuring the titer and potency of viral vector particles
|
|
AU2019354793A1
(en)
|
2018-10-05 |
2021-05-13 |
Voyager Therapeutics, Inc. |
Engineered nucleic acid constructs encoding AAV production proteins
|
|
US20210371470A1
(en)
|
2018-10-12 |
2021-12-02 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
|
WO2020081490A1
(en)
|
2018-10-15 |
2020-04-23 |
Voyager Therapeutics, Inc. |
EXPRESSION VECTORS FOR LARGE-SCALE PRODUCTION OF rAAV IN THE BACULOVIRUS/Sf9 SYSTEM
|
|
MX2021005720A
(es)
|
2018-11-16 |
2021-07-21 |
Astellas Pharma Inc |
Metodo para tratar la distrofia muscular mediante el direccionamiento del gen de utrofina.
|
|
CA3125770A1
(en)
|
2019-01-18 |
2020-07-23 |
Voyager Therapeutics, Inc. |
Methods and systems for producing aav particles
|
|
CA3130221A1
(en)
|
2019-02-28 |
2020-09-03 |
Benitec IP Holdings Inc. |
Compositions and methods for treating oculopharyngeal muscular dystrophy (opmd)
|
|
KR20210148273A
(ko)
*
|
2019-04-08 |
2021-12-07 |
제네똥 |
근육 발현을 위한 하이브리드 프로모터
|
|
EP3966227A1
(en)
|
2019-05-07 |
2022-03-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
|
|
JP7565620B2
(ja)
|
2019-05-28 |
2024-10-11 |
株式会社モダリス |
Ｄｍｐｋ遺伝子を標的とした筋ジストロフィーの治療方法
|
|
BR112022002889A2
(pt)
|
2019-08-16 |
2022-05-17 |
Modalis Therapeutics Corp |
Método para tratar distrofia muscular tendo como alvo o gene lama1
|
|
WO2021046155A1
(en)
|
2019-09-03 |
2021-03-11 |
Voyager Therapeutics, Inc. |
Vectorized editing of nucleic acids to correct overt mutations
|
|
WO2021202651A1
(en)
|
2020-04-01 |
2021-10-07 |
Voyager Therapeutics, Inc. |
Redirection of tropism of aav capsids
|
|
CA3180222A1
(en)
|
2020-04-15 |
2021-10-21 |
Voyager Therapeutics, Inc. |
Tau binding compounds
|
|
US12630842B2
(en)
|
2020-05-13 |
2026-05-19 |
Voyager Therapeutics, Inc. |
Redirection of tropism of AAV capsids
|
|
WO2021230385A1
(en)
|
2020-05-15 |
2021-11-18 |
Astellas Pharma Inc. |
Method for treating muscular dystrophy by targeting utrophin gene
|
|
WO2021247995A2
(en)
|
2020-06-04 |
2021-12-09 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating neuropathic pain
|
|
WO2022056291A1
(en)
*
|
2020-09-11 |
2022-03-17 |
Nature Technology Corporation |
Muscle-specific hybrid promoter
|
|
WO2022073041A2
(en)
|
2020-09-30 |
2022-04-07 |
NGGT, Inc. |
Dual functional expression vectors and methods of use thereof
|
|
JP2023548746A
(ja)
|
2020-10-13 |
2023-11-21 |
クリヤ セラピューティクス インコーポレイテッド |
サイトカインをコードする核酸を送達するためのウイルスベクターコンストラクトおよびがんを処置するためのその使用
|
|
WO2022114243A1
(en)
|
2020-11-25 |
2022-06-02 |
Astellas Pharma Inc. |
Method for treating muscular dystrophy by targeting dmpk gene
|
|
CA3206107A1
(en)
|
2021-01-26 |
2022-08-04 |
Brian Furmanski |
Vector constructs for delivery of nucleic acids encoding therapeutic anti-tnf antibodies and methods of using the same
|
|
EP4036238A1
(en)
*
|
2021-01-27 |
2022-08-03 |
The University Court of the University of Edinburgh |
Functional nucleic acid molecule and method
|
|
IL304956A
(en)
|
2021-02-12 |
2023-10-01 |
Merand Pharmaceuticals Inc |
Agents, compositions, and methods for the treatment of hypoxia and ischemia-related disorders
|
|
EP4301860A1
(en)
|
2021-03-04 |
2024-01-10 |
Kriya Therapeutics, Inc. |
Viral vector constructs incorporating dna for inhibiting toll like receptors and methods of using the same
|
|
WO2023012313A1
(en)
*
|
2021-08-04 |
2023-02-09 |
Genethon |
Hybrid promoters for gene expression in muscles and in the cns
|
|
WO2023023055A1
(en)
|
2021-08-16 |
2023-02-23 |
Renagade Therapeutics Management Inc. |
Compositions and methods for optimizing tropism of delivery systems for rna
|
|
TW202328067A
(zh)
|
2021-09-14 |
2023-07-16 |
美商雷納嘉德醫療管理公司 |
環狀脂質及其使用方法
|
|
WO2023044343A1
(en)
|
2021-09-14 |
2023-03-23 |
Renagade Therapeutics Management Inc. |
Acyclic lipids and methods of use thereof
|
|
WO2023044483A2
(en)
|
2021-09-20 |
2023-03-23 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
|
JP2025503637A
(ja)
|
2022-01-09 |
2025-02-04 |
クリヤ セラピューティクス， インコーポレイテッド |
治療用抗ｉｇｆ－１ｒ抗体をコードする核酸の送達のためのベクター構築物およびそれを使用する方法
|
|
US20250243510A1
(en)
*
|
2022-03-16 |
2025-07-31 |
Rutgers, The State University Of New Jersey |
Controlled muscle-specific gene delivery
|
|
CA3255619A1
(en)
|
2022-04-07 |
2023-10-12 |
Renagade Therapeutics Management Inc. |
CYCLIC LIPIDS AND LIPID NANOPARTICLES (LPNs) FOR THE SUPPLY OF NUCLEIC ACIDS OR PEPTIDES INTENDED FOR USE IN VACCINATION AGAINST INFECTIOUS AGENTS
|
|
WO2023220695A2
(en)
|
2022-05-13 |
2023-11-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
|
US20250243263A1
(en)
|
2022-06-22 |
2025-07-31 |
Voyager Therapeutics, Inc. |
Tau binding compounds
|
|
JP2025526502A
(ja)
*
|
2022-07-11 |
2025-08-13 |
ヴァイタ セラピューティクス， インコーポレイテッド |
筋ジストロフィーを処置するための治療用サテライト細胞の製造
|
|
JP2025535203A
(ja)
|
2022-09-15 |
2025-10-23 |
ボイジャー セラピューティクス インコーポレイテッド |
タウ結合化合物
|
|
AU2024287813A1
(en)
|
2023-07-07 |
2026-01-22 |
Kriya Therapeutics, Inc. |
Periocular delivery of aav vectors for treating ophthalmic pathologies
|